Current role
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2024-01-01–present
Kyle W. Gano
Board Member
Neurocrine Biosciences Inc (NBIX)Equibles does not estimate personal net worth.
Get an email with a short summary when Neurocrine Biosciences Inc publishes a filing, an earnings call transcript or a press release.
Get NBIX alertsAbout Kyle W. Gano
Kyle W. Gano is recorded as Board Member at Neurocrine Biosciences Inc (NBIX) since January 1, 2024 and CEO at Neurocrine Biosciences Inc (NBIX). The newest filing on record that lists Kyle W. Gano as CEO and Board Member at Neurocrine Biosciences Inc (NBIX) is dated April 15, 2026. The proxy statement of Neurocrine Biosciences Inc reports total compensation of $13,448,935 for Kyle W. Gano in fiscal 2025, including a base salary of $920,000. Disclosed compensation is on record for 8 fiscal years. Neurocrine Biosciences Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Neurocrine Biosciences Inc includes Kevin Gorman (CEO and Board Member), Kyle Gano, Ph.D. (CEO and Board Member), Matthew C. Abernethy (CFO) and 7 others.
Affiliation history
-
Current
2024-01-01–present
Last confirmed April 15, 2026
-
Current
Start not stated–present
Last confirmed April 15, 2026
-
Neurocrine Biosciences Inc (NBIX)
Proxy statement
Start not stated–2024-04-10
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Neurocrine Biosciences Inc
- Kevin Gorman CEO, Board Member
- Kyle Gano, Ph.D. CEO, Board Member
- Matthew C. Abernethy CFO
- Christine A. Poon Board Member
- Gary A. Lyons Board Member
- George J. Morrow Board Member
- Johanna Mercier Board Member
- Kevin C. Gorman Board Member
- Kevin C. Gorman, Ph.D. Board Member
- Kyle W. Gano, Ph.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Neurocrine Biosciences Inc (NBIX) | Chief Executive Officer | $920,000 | $13,448,935 |
| 2024 | Neurocrine Biosciences Inc (NBIX) | Chief Executive Officer | $698,217 | $8,535,422 |
| 2023 | Neurocrine Biosciences Inc (NBIX) | Chief Executive Officer | $602,912 | $5,990,215 |
| 2022 | Neurocrine Biosciences Inc (NBIX) | Chief Executive Officer | $550,605 | $5,421,657 |
| 2021 | Neurocrine Biosciences Inc (NBIX) | Chief Business Development and Strategy Officer | $517,000 | $5,811,324 |
| 2020 | Neurocrine Biosciences Inc (NBIX) | Chief Business Development and Strategy Officer | $487,700 | $7,211,940 |
| 2019 | Neurocrine Biosciences Inc (NBIX) | Chief Development and Strategy Officer | $443,400 | $4,725,972 |
| 2018 | Neurocrine Biosciences Inc (NBIX) | Chief Development and Strategy Officer | $403,100 | $4,568,241 |
Recent activity
No call appearances or filed executive changes recorded yet.